Navigation Links
Less HRT, Fewer Cases of Possible Breast Cancer Precursor

As hormone use declined, so did incidence of abnormal cells in milk ducts, study finds

THURSDAY, Nov. 12 (HealthDay News) -- Declining use of hormone replacement therapy may be driving down rates of a condition called "atypical ductal hyperplasia," a known risk factor for breast cancer, new research suggests.

This is the first time a link has been found between atypical ductal hyperplasia -- abnormal cells in the breast's milk ducts -- and hormone therapy, said Diana Miglioretti, senior author of a paper published in the November issue of Cancer Epidemiology, Biomarkers & Prevention.

"It sounds like another reason not to take hormones," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge.

"This is part of a pattern that combined use of hormone therapy with both estrogen and progesterone does something to a woman's breast that predisposes them to atypical ductal hyperplasia, which is felt to be a precursor to certain types of malignancies," Brooks added.

If atypical ductal hyperplasia does turn out to be a precursor to breast cancer, this link would be a good indicator of how use of hormone therapy -- often used for menopausal symptoms such as hot flashes -- can help spur malignancy.

The findings are in keeping with other recent research showing a decline in breast cancer rates since the release of results from the Women's Health Initiative, a major trial that caused many women to stop taking combined (estrogen plus progesterone) hormone therapy.

The Women's Health Initiative was halted in July of 2002 after researchers found higher risks of heart attacks and breast cancer in women taking the hormone supplements compared with placebo.

Since that time, use of hormone replacement therapy (HRT) has experienced a precipitous decline.

According to experts, women diagnosed with atypical ductal hyperplasia have a three to five times increased risk of developing breast cancer, either in the same breast or the opposite breast.

Atypical ductal hyperplasia "is a benign condition but it is a risk factor for breast cancer. It's not clear if it's a precursor to breast cancer," said Miglioretti, who is a senior investigator with the Group Health Research Institute in Seattle. "This sheds light on more of the breast process, how HRT affects breast cancer."

Miglioretti and her co-authors analyzed almost 2.5 million screening mammographies from samples provided by the Breast Cancer Surveillance Consortium. The mammograms were done between 1996 and 2005.

In 1999, atypical ductal hyperplasia was found in 5.5 per 10,000 mammograms but by 2005 had declined to only 2.4 per 10,000, a drop of more than half. This occurred despite an increase over time of rates of mammography, which tend to pick up the abnormality.

Meanwhile, breast cancer cases in women with atypical ductal hyperplasia declined from 4.3 per 10,000 mammograms in 2003 to 3.3 per 10,000 mammograms in 2005.

And postmenopausal use of hormone therapy dropped from 35 percent to 11 percent.

The study also revealed that cancers associated with atypical ductal hyperplasia tend to be less aggressive, lending support to the theory that less aggressive and more aggressive cancers develop differently, the authors stated.

One breast cancer expert said the new study dovetails with recent trends in breast cancer incidence.

"The finding they report is consistent with [previous] observations that suggested there was a drop in incidence of breast cancer in about 2003 and it coincided with when the Women's Health Initiative reported that estrogen-plus-progesterone use was associated with an increased risk of heart attacks as well as a slight increased incidence of breast cancer risk," said Dr. James Liu, chairman of obstetrics and gynecology at MacDonald Women's Hospital, Case Medical Center, University Hospitals in Cleveland. "The association caused many women to either question their need to be on [hormone therapy] or stopping it."

But, cautioned Liu, "the data is not strong enough to say this observation was caused by [a decline in hormone use] but it is a very strong association."

More information

There's more on hormone therapy and cancer at the U.S. National Cancer Institute.

SOURCES: Diana Miglioretti, Ph.D., senior investigator, Group Health Research Institute, Seattle; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; James Liu, M.D., chairman, department of obstetrics and gynecology, MacDonald Women's Hospital, Case Medical Center, University Hospitals, Cleveland; November 2009, Cancer Epidemiology, Biomarkers & Prevention

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Black gay men, lesbians, have fewer mental disorders than whites, says Mailman School of PH study
2. Fewer adverse cardiac events at one year
3. Hispanics Receive Fewer Surgeries for Vascular Disease
4. Fewer Women Getting Mammograms
5. Fewer Children Outgrowing Allergies to Milk, Eggs
6. Rural Residents Get Fewer Organ Transplants: Study
7. Children who have an active father figure have fewer psychological and behavioral problems
8. Single reader with CAD more efficient, yields fewer false positives, and possibly more sensitive
9. Fewer Steps Per Day Send Disease Markers Up
10. Breast Cancer Radiation Therapy Works in Fewer, But Higher Doses
11. Overweight kids have fewer cavities, new study shows
Post Your Comments:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... will provide scholarships for people struggling with eating disorders as a result of ... the second annual event, held at Fox Run Golf Club in Eureka, will ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... that it has undertaken significant expansion of its current state of the art ... part of PharmaTech’s strategy to increase its manufacturing capacity as well as to ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a ... (TSC), as well as raising public awareness of the disorder while helping to ... third donation of $35,000 to bolster progress at the Tuberous Sclerosis Complex Center ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... treatment, is offering lower prices in an early celebration of the early holiday ... promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing is ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Dr. Todd S. ... offer laser services to many of his patients. Dr. Afferica now uses the BIOLASE ... reduce the amount of time the doctor uses other traditional cutting tools, such as ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... LYON , Frankreich, November 25, 2015 ... hat heute bekanntgegeben, dass sie eine Lizenz für das ... Inserm, Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo ... 2009 von FUI AAP8 ins Leben gerufenen und von ... NATHEB-Programms wurde FXR als ein Behandlungsziel für HBV identifiziert, ...
(Date:11/24/2015)... 24, 2015  Natera, Inc. (Nasdaq: ... testing and the analysis of circulating cell-free ... at the 27 th  Annual Piper Jaffray ... p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, ... activities and financial outlook.  ...
(Date:11/24/2015)... COMMACK, New York , 24. November ... Hersteller des Avery Breathing Pacemaker Systems, ist ... Ph.D., als Clinical Consultant bekannt geben zu ... -->   --> ... Stockholm (Schweden). Von 1984-1986 ...
Breaking Medicine Technology: